Capricor Therapeutics Inc【CAPR】株式ニュース

個人投資家向けのプロ仕様のツール。

プレミアム

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

–Advisory Committee meeting scheduled for July 29, 2026––Company's Biologics License Application on track with...

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

Deramiocel demonstrates durable skeletal and cardiac muscle benefit over five years in the HOPE-2 OLE studyPUL...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144/A - Report of proposed sale of securities: [Amend]

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

ed3/6me 3日前

Grabbed on fri. @26. Washappy....but....darn!

👍️0

D-bol 3日前

I’m still hanging in there. Hopefully something changes soon.

👍️0

ed3/6me 3日前

Second day. In a row,good news and a drop in price?

You think one of the owners sold some today?

👍️0

gbrown6332 6日前

Very comfortable add of shares today.

💯 1

ed3/6me 6日前

Feel like a whore here but back in at 26$. Volatility is our friend while waiting for results

👍️0

ed3/6me 1月前

Think it will peek at 40 again this time

👍️0

Topfuel 1月前

Got a few been flipping was in on last big run

👍️0

ed3/6me 1月前

Grab some or regret soon

👍️0

ed3/6me 1月前

Am not complaining but had been timing ups and owns great here. Was a little off this time

Deramiocel approval + Capricor markets in US = $100+

💯 1

ed3/6me 2月前

Read between the lines in their suit.

👍️0

ed3/6me 2月前

Thank you for upping my count here everyone who sold today

👍️0

ed3/6me 2月前

take advantage while low!! i did

👍️ 1 💯 1

ed3/6me 2月前

What shook other people out took me back

👍 1 💯 1

Zardiw 2月前

Really nice $CAPR Article:

https://talkmarkets.com/article/capricors-pdufa-on-deramiocel-offers-excellent-risk-reward-for-august-expiration-1776703236

Z

🔥 1

dia76ca 3月前

1-Year Return
CAPR
252.23%
S&P 500
33.02%

3-Year Return
CAPR
675.23%
S&P 500
69.60%

5-Year Return
CAPR
746.76%
S&P 500
67.67%

There are a series of BIG catalysts coming... starting within the next few weeks or months!
* The FDA approval of Deramiocel for DMD can happen at any time. The PDUFA date of Aug.22 has been set, so approvals can come any day before then. This will trigger hundreds of millions in milestones and a large voucher (worth about $200 million)
* A large European partnership for Deramiocel is expected to follow. This will again spark hundreds of millions in milestones. Will it be with Nippon Shinyaku (NS) or with a Big Pharma?
* Deramiocel entry into the Japanese market with NS will soon follow with more milestones.
* Sales of Deramiocel for DMD in the US will occur soon after approval. NS already has a sales force in place and Capricor has stockpiled doses for 150 patients. By the end of 2027 they expect to serve over 3,000 patients.
* There will be updates later this year about "several" StealthX exosome delivered therapeutics ready for IND's in 2027. This is in addition to any further vaccine trials likely to continue to be funded by NIAID.
* Capricor already has $300 million in cash and no debt. Lots of catalysts and lots of cash coming soon!

👍 1

ed3/6me 3月前

All the people touting this... When will it kick in?

👍️0

dia76ca 3月前

Absolutley! I will hold all my Capricor shares until the buy-out. In 3 or 4 years the cardiomyopathy platform and the StealthX exosome drug delivery platform should be worth many billions. Capricor is cash rich now but will be even richer when Deramiocel is approved. And I look forward to 3 or 4 StealthX therapeutic exosome IND's in 2027.

Catalyst rich! Cash rich! Do your own dd !
1. With August 22 PDUFA date Deramiocel FDA approval can come any day!
2. Phase 3 data article in medical journal
3. Latest Share Price targets by analysts now $60-+
4. Deramiocel European + ROW PARTNERSHIP (with NS or Big Pharma ?) Upfront/ Milestones likely $1 Billion plus!
5. NS milestones for Deramiocel in Japan
6. Becker will advance (approval or trial)
7. StealthX Covid vaccine trial(NIAID funded) likely to continue.
8. Several (3+) StealthX Therapeutics IND's in 2027
9. US earnings in 2026
10. Clean rooms added.
11. Quarterly Report updates
12. Buyout chatter!
Capricor is cash rich with $300 million cash: $80 million NS milestone on US approval and a PRV worth about $200 million ,$605 million US milestones+ new partner upfronts and milestones ! ( $2 + Billion milestones and cash?). NICE!

🚀 1

ed3/6me 3月前

Probably those who get cheap shares as pay.

👍️0

MyFiveCents 3月前

I see several insiders just sold bunch of shares.
Do they know something that we don't?

👍️0

ed3/6me 3月前

Am tired of being poor.... Let's go!

👍️0

ed3/6me 3月前

love ping pong. a few more shares from waffling and am back here again

👍️0

ed3/6me 4月前

The market touts it too as the mark is now raised from 50 to 63

👍️0

dia76ca 4月前

If you have not seen it before, have a look at the slides of Dr. Craig McDonald's presentation of the phase 3 data at the recent MDA Conference.
The data is strong!
https://d1io3yog0oux5.cloudfront.net/_5b99e26ce1ff49eed4f7d3b537a39b87/capricor/db/2227/21507/pdf/MDA+2026+CAPR+3.11.26+late-breaker.pdf

👍️0

ed3/6me 4月前

Get a boost on value and watch it go down

👍️0

D-bol 4月前

Going to be fun this week

👍️0

dia76ca 4月前

Submission Complete! Oral Presentation at Conference March 11 ! And then...
1. Phase 3 data article published in leading medical journal
2. FDA announcing new PDUFA date
3. Deramiocel FDA approval
4. Deramiocel European + ROW PARTNERSHIP
(with NS or Big Pharma ?)
5. More NS milestones for Deramiocel in Japan
6. Becker will advance (approval or trial)
7. StealthX Covid vaccine results (NIAID funded)
8. StealthX Big Pharma and/or more NIAID PARTNERSHIP(s)
9. Deramiocel US earnings in 2026
10. More Analysts
11. Quarterly Report updates
12. Increased Share Price Targets by Analysts
Followed by increased chatter about buyout !

Meanwhile Capricor is cash rich with some $330 million cash; an $80 million NS milestone upon US approval and a PRV worth as much as $200 million ,$605 million sales milestones+ new partnership upfronts and milestones !

🔥 1

dia76ca 4月前

I think it is a certainty that Capricor will be bought out at some time in the next few years!
Deramiocel alone makes it a great addition to a Big Pharm pipeline. DMD, Becker and other
cardiomyopathies will provide a large and growing revenue stream beginning in 2026!

The StealthX exosome platform drug delivery has an even larger potential. Capricor has
several vaccines ready for the clinic right now! And there scores of Therapeutic applications
including rare diseases, oncology and inflammatory diseases. IMO StealthX revenues will
exceed those of Deramiocel!

And the Marban Labs at Cedars-Sinai have come up with an amazing drug in TY1. It is
ready to go into the clinic and its many applications will make it a Super-Blockbuster!
I see an upcoming bidding war for Capricor. Great Science! Great Future!

👍️0

XWAVXALMIMAN 4月前

Nice move today. How high can we go? Do you think a larger company might buy us?

👍️0

dia76ca 4月前

Submission over soon! Then...
1. Phase 3 data article published in leading medical journal
2. FDA announcing new PDUFA date
3. Deramiocel FDA approval
4. Deramiocel European + ROW PARTNERSHIP
(with NS or Big Pharma ?)
5. More NS milestones for Deramiocel in Japan
6. Becker will advance (approval or trial)
7. StealthX Covid vaccine results (NIAID funded)
8. StealthX Big Pharma and/or more NIAID PARTNERSHIP(s)
9. Deramiocel US earnings in 2026
10. More Analysts
11. Quarterly Report updates
12. Increased Share Price Targets by Analysts
13. TY1 from Marban Labs enters clinic
14. Increased chatter about buyout !
Capricor is cash rich with some $330 million cash; an $80 million NS milestone upon US approval and a PRV worth as much as $200 million ,$605 million sales milestones+ new partnership upfronts and milestones !
Nice to be long!

👍️0

XWAVXALMIMAN 4月前

Ed, try XRP. I’m down from 40,000 CAPR to 15,000. I still have confidence in CAPR but I have sold between 25-31 and buy 15-30,000 XRP by selling 1-2000 CAPR. I think both will double but XRP will easily triple .

👍️0

ed3/6me 5月前

In again. Only play I'm in making money

👍️0

dia76ca 5月前

New Corporate Presentation. Great read!
https://d1io3yog0oux5.cloudfront.net/_fc552ab0de70aea3033355e9b059d762/capricor/db/2227/21490/pdf/CAPR+Feb+2026+%28Corporate+Deck%29.pdf

👍 1

ed3/6me 5月前

so does tang own 13% or 19%?

👍️0

ed3/6me 6月前

Hope there's good news in morning

👍️0

dia76ca 6月前

The BIOTECH TV presentation by Linda Marban on TUESDAY January 13, 2026 could be very important. I don't know if it is the same people that did the Bio Tech Health X presentation on August 9 2024 but Linda got a lot of information across in 22 minutes!
https://www.bing.com/videos/riverview/relatedvideo?q=biotech+tv+jan.13+2026+linda+marban&cvid=d720dcadb7bd433c8c271918b2edf677&gs_lcrp=EgRlZGdlKgYIABBFGDkyBggAEEUYOTIGCAEQABhAMgYIAhAAGEDSAQk0NzE1M2owajSoAgiwAgE&adppc=EDGEESS&PC=ACTS&ru=%2fsearch%3fq%3dbiotech%2btv%2bjan.13%2b2026%2blinda%2bmarban%26cvid%3dd720dcadb7bd433c8c271918b2edf677%26gs_lcrp%3dEgRlZGdlKgYIABBFGDkyBggAEEUYOTIGCAEQABhAMgYIAhAAGEDSAQk0NzE1M2owajSoAgiwAgE%26FORM%3dANAB01%26adppc%3dEDGEESS%26PC%3dACTS&mmscn=vwrc&mid=E34311F4A25E1221E979E34311F4A25E1221E979&FORM=WRVORC&ntb=1&msockid=9c291325ef0411f0900cab89376f4f32

👍️0

ed3/6me 6月前

lets get it on now. love me some news....please

👍️0

dia76ca 6月前

What does Capricor's financial situation look like in 2026?
* It has about $300 million cash on hand.
* With Deramiocel approval it will receive $80 million from a NS milestone and a PRV worth at least $150 million.
* They have hundreds of millions due in upfront and milestones from NS when Deramiocel is advanced in Japan.
* There will be hundreds of millions due in upfront and milestones when they sign an European/ROW partnership with NS or a Big Pharma.
* There will be Deramiocel revenue in the US beginning in 2026. And there will be sales milestones from NS !
* They have said that they intend to partner the exosome based products from the StealthX PLATFORM. Will they have many partners with many products? Or will there be one large partnership with Big Pharma ?
Either way there will be upfront, milestone and royalty revenues starting in 2026.
CAPRICOR has a solid financial base in 2026. And it will only get stronger year after year.

👍 1

dia76ca 6月前

2026 is the pivotal year for Capricor!
There should be 6 big 2026 catalysts...
1. Deramiocel FDA approval
2. Deramiocel European + ROW PARTNERSHIP
3. Becker will be advanced (approval or trial)
4. StealthX Covid vaccine results
5. StealthX BP and NIAID PARTNERSHIP(s)
6. Deramiocel US earnings in 2026
Capricor is already CASH RICH and another $80 million will come with Deramiocel approval as will a PRV which recently have been sold for over $150 million. And Deramiocel and StealthX PARTNERSHIP(s) will bring upfront, milestone and royalty payments !
All these catalysts will dramatically increase the share price. A partnership/buyout similar to Genentech is possible in the next few years. Capricor is the new Genentech of the Exosome world IMO. Great 2026 for all patients and investors!

👍️0

dia76ca 7月前

Register for this event if you want an update on Wednesday, Dec. 17 at 1pm ET. Just scroll down to get the registration information.
https://www.parentprojectmd.org/events/

👍️0

XWAVXALMIMAN 7月前

I had trouble selling at 35 and ended up selling some at 25 and then 30 and sold a little more at 28. I had 38,000 for many years buying in 2020-2021 at 3-5. I’m down to 23,000 shares now and plan to hold but I don’t trust RFK and FDA. I hope we get approval but what if they say it is too expensive?
When does everyone think we will get an answer from FDA? I’ll try to check here more regularly.

👍️0

dia76ca 7月前

Here Linda explains how Deramiocel works in under 7 minutes. Well worth a listen !
https://www.cgtlive.com/view/marban-evaluating-capricor-cardiomyopathy-cell-therapy-deramiocel-dmd

👍️0

dia76ca 7月前

I agree with those who think the BLA submission to the FDA could happen before the end of this year. That news alone could take the share price to around $40.
But what will happen in 2026?
There should be 5 big 2026 catalysts...
1. Deramiocel FDA approval
2. Deramiocel European + ROW partnership
3. StealthX vaccine results
4. StealthX BP and NIAID partnership(s)
5. Deramiocel US earnings in 2026
Capricor is already CASH RICH and another $80 million will come with approval as will a PRV which recently have been sold for over $150 million.
Good partnerships could bring the share price up to the $200 range IMO. But it could be bought out for much more at any time.

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Capricor Therapeutics Inc (CAPR)

個人投資家向けのプロ仕様のツール。

Capricor Therapeutics Inc (CAPR) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Capricor Therapeutics to Present at Upcoming Investor Conferences

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144/A - Report of proposed sale of securities: [Amend]

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

CAPR Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Capricor Therapeutics Inc (CAPR)

個人投資家向けのプロ仕様のツール。

Capricor Therapeutics Inc (CAPR) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Capricor Therapeutics to Present at Upcoming Investor Conferences

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144/A - Report of proposed sale of securities: [Amend]

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

CAPR Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する